ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.738,81
-0,72%
S&P 500
5.297,10
-0,21%
Dow Jones
39.869,38
-0,10%
Euro vs US Dollar
1,08598
-0,07%
Bitcoin
65.267,43
0,04%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Bellerophon Therapeutics Inc (BLPH)

  7. Bellerophon Therapeutics Inc (BLPH) News

BLPH

Bellerophon Therapeutics (BLPH)

Bellerophon Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BLPH
DatumZeitQuelleÜberschriftSymbolFirma
30/01/202415h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
26/01/202420h31Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BLPHBellerophon Therapeutics Inc
26/01/202416h46Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BLPHBellerophon Therapeutics Inc
22/01/202421h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
10/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
03/01/202419h49Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BLPHBellerophon Therapeutics Inc
27/10/202316h50Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:BLPHBellerophon Therapeutics Inc
17/10/202302h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h59Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h59Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h58Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h58Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h57Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h56Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h56Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h55Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLPHBellerophon Therapeutics Inc
16/10/202319h54Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLPHBellerophon Therapeutics Inc
13/10/202316h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
13/10/202314h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
14/08/202322h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BLPHBellerophon Therapeutics Inc
07/08/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
24/07/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
20/07/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
14/07/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
29/06/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BLPHBellerophon Therapeutics Inc
29/06/202322h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLPHBellerophon Therapeutics Inc
12/06/202312h45Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BLPHBellerophon Therapeutics Inc
09/06/202322h13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BLPHBellerophon Therapeutics Inc
09/06/202322h12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BLPHBellerophon Therapeutics Inc
09/06/202322h12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BLPHBellerophon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BLPH

Kürzlich von Ihnen besucht

BIBX
XENOUSDT
Xenoverse
NASDAQ
GCBC
Greene County Bancorp
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten